Enhancer of zeste homologue 2 (EZH2), the catalytic subunit of Polycomb repressive
complex 2 (PRC2), has attracted broad research attention in the past few years because of …

During the course of malignant cancer progression, neoplastic cells undergo dynamic and
reversible transitions between multiple phenotypic states, the extremes of which are defined …

Polycomb Group (PcG) proteins are transcriptional repressors that epigenetically modify
chromatin and participate in the establishment and maintenance of cell fates. These proteins …

EZH2 is the catalytic subunit of Polycomb repressive complex 2 (PRC2), which is a highly
conserved histone methyltransferase that targets lysine-27 of histone H3. This methylated …

Polycomb group (PcG) proteins are epigenetic gene silencers that are implicated in
neoplastic development. Their oncogenic function might be associated with their well …

Inhibition of the protein kinase WEE1 synergizes with chemotherapy in preclinical models
and WEE1 inhibitors are being explored as potential cancer therapies. Here, we investigate …

Diethylstilbestrol (DES) and bisphenol-A (BPA) are estrogen-like endocrine-disrupting
chemicals that induce persistent epigenetic changes in the developing uterus. However …

Dietary phytochemicals are currently being studied with great interest due to their ability to
regulate the epigenome resulting in prevention of cancer. Some natural botanicals have …

Cancer is perceived as a heterogeneous group of diseases that is characterized by aberrant
patterns of gene expression. In the last decade, an increasing amount of data has pointed to …

Polycomb group proteins have long been linked to the occurrence of different forms of
cancer. Polycomb proteins form at least two distinct complexes, the Polycomb-repressive …